Mohammed A. Hadis, Ignacio Insua, Farah N. S. Raja, Álvaro Vila, William M. Palin, Michael R. Milward, Paul R. Cooper, Sarah A. Kuehne, Owen Addison, Paco Fernandez-Trillo
{"title":"Human Leukocyte Elastase Triggered Nanoparticles for Targeted Antimicrobial Delivery and Oral Microbial Modulation","authors":"Mohammed A. Hadis, Ignacio Insua, Farah N. S. Raja, Álvaro Vila, William M. Palin, Michael R. Milward, Paul R. Cooper, Sarah A. Kuehne, Owen Addison, Paco Fernandez-Trillo","doi":"10.1002/anbr.202500303","DOIUrl":null,"url":null,"abstract":"<p>This study investigated targeted antimicrobial delivery through enzyme-responsive polyelectrolyte complex (PIC) nanoparticles of peptides and antimicrobials. Nanoparticles released chlorhexidine upon enzymatic activation by human leukocyte elastase (<i>HLE</i>), mimicking conditions present at inflamed or infected sites, and utilized as a semi-specific trigger for oral disease. Peptides <b>P1-P4</b> and <b>P6-P8</b> were tailored with <i>HLE</i> cleavable sequence alanine–alanine–proline–valine (AAPV) and flanked with cysteine and glutamic acid residues to enhance solubility, disulfide oxidation, and <i>HLE</i> sensitivity and specificity. Dynamic light scattering confirmed particle formation across various antimicrobial biguanide and peptide carboxylate ratios (N:COOH), with optimal size distribution and autocorrelation profiles observed for <b>P7</b> (ECAAPVCE; N:COOH of 1:0.3). <b>P7</b>-chlorhexidine-based nanoparticles demonstrated structural stability in physiological conditions. Nanoparticle treatment of commensal <i>Streptococcus sanguinis</i>, and pathogenic <i>Streptococcus mutans</i> and <i>Porphyromonas gingivalis</i> delayed bacterial growth in a time-, concentration-, and <i>HLE</i>-dependent manner (<i>p</i> < 0.05). Subinhibitory effects without <i>HLE</i> suggested residual chlorhexidine was below the minimum inhibitory concentration, while the presence of <i>HLE</i> enhanced antimicrobial effects, leading to complete inhibition of pathogenic species and transient growth inhibition of commensal species. These findings support development of <i>HLE</i>-responsive nanoparticle systems for targeted antimicrobial delivery, with potential for modulating microbial communities and providing site-specific therapy in oral and other inflammatory infections.</p>","PeriodicalId":29975,"journal":{"name":"Advanced Nanobiomed Research","volume":"6 8","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2026-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.202500303","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Nanobiomed Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/anbr.202500303","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
This study investigated targeted antimicrobial delivery through enzyme-responsive polyelectrolyte complex (PIC) nanoparticles of peptides and antimicrobials. Nanoparticles released chlorhexidine upon enzymatic activation by human leukocyte elastase (HLE), mimicking conditions present at inflamed or infected sites, and utilized as a semi-specific trigger for oral disease. Peptides P1-P4 and P6-P8 were tailored with HLE cleavable sequence alanine–alanine–proline–valine (AAPV) and flanked with cysteine and glutamic acid residues to enhance solubility, disulfide oxidation, and HLE sensitivity and specificity. Dynamic light scattering confirmed particle formation across various antimicrobial biguanide and peptide carboxylate ratios (N:COOH), with optimal size distribution and autocorrelation profiles observed for P7 (ECAAPVCE; N:COOH of 1:0.3). P7-chlorhexidine-based nanoparticles demonstrated structural stability in physiological conditions. Nanoparticle treatment of commensal Streptococcus sanguinis, and pathogenic Streptococcus mutans and Porphyromonas gingivalis delayed bacterial growth in a time-, concentration-, and HLE-dependent manner (p < 0.05). Subinhibitory effects without HLE suggested residual chlorhexidine was below the minimum inhibitory concentration, while the presence of HLE enhanced antimicrobial effects, leading to complete inhibition of pathogenic species and transient growth inhibition of commensal species. These findings support development of HLE-responsive nanoparticle systems for targeted antimicrobial delivery, with potential for modulating microbial communities and providing site-specific therapy in oral and other inflammatory infections.
期刊介绍:
Advanced NanoBiomed Research will provide an Open Access home for cutting-edge nanomedicine, bioengineering and biomaterials research aimed at improving human health. The journal will capture a broad spectrum of research from increasingly multi- and interdisciplinary fields of the traditional areas of biomedicine, bioengineering and health-related materials science as well as precision and personalized medicine, drug delivery, and artificial intelligence-driven health science.
The scope of Advanced NanoBiomed Research will cover the following key subject areas:
▪ Nanomedicine and nanotechnology, with applications in drug and gene delivery, diagnostics, theranostics, photothermal and photodynamic therapy and multimodal imaging.
▪ Biomaterials, including hydrogels, 2D materials, biopolymers, composites, biodegradable materials, biohybrids and biomimetics (such as artificial cells, exosomes and extracellular vesicles), as well as all organic and inorganic materials for biomedical applications.
▪ Biointerfaces, such as anti-microbial surfaces and coatings, as well as interfaces for cellular engineering, immunoengineering and 3D cell culture.
▪ Biofabrication including (bio)inks and technologies, towards generation of functional tissues and organs.
▪ Tissue engineering and regenerative medicine, including scaffolds and scaffold-free approaches, for bone, ligament, muscle, skin, neural, cardiac tissue engineering and tissue vascularization.
▪ Devices for healthcare applications, disease modelling and treatment, such as diagnostics, lab-on-a-chip, organs-on-a-chip, bioMEMS, bioelectronics, wearables, actuators, soft robotics, and intelligent drug delivery systems.
with a strong focus on applications of these fields, from bench-to-bedside, for treatment of all diseases and disorders, such as infectious, autoimmune, cardiovascular and metabolic diseases, neurological disorders and cancer; including pharmacology and toxicology studies.